基于VOSviewer的2019新型冠状病毒病中医临床诊疗可视化分析＊

目的 通过对公开发表在网络和数据库的有关中医药治疗2019新型冠状病毒肺炎（corona virus disease 2019，COVID-19）的文献进行方、药、证的可视化分析，客观全面的对COVID-19的中医药治疗进行探讨，为现代中医临床诊疗提供参考。方法 本文选用运用文献计量学方法和VOSviewer可视化软件对纳入文献中的用药情况进行数据拆分、整理和分析。结果 本研究高质量数据的主要期刊来源是核心期刊《中医杂志》；新冠临床用方以解表清热剂、开窍补益剂、辟秽祛湿剂为主；临床用药以解表药、清热解毒药、化湿祛痰药以及补益药为主；临床治病思路以六经辨证、三焦辨证和卫气营血辨证理论为指导；临床常见证型为湿、热、寒、毒相关证型；重视新冠前期预防以及后期恢复调养；治疗过程用药考究，注重养阴与祛邪并进。结论 新冠的中医临床诊治考病全面，并注重养阴与祛邪并进，可为官方制定治疗方案提供参考。     

中药复方配伍的研究方法及其进展

中药复方是由2味或2味以上中药遵循中医理论组合而成的方剂。多味中药在合适的剂量配比之下,协同发挥作用,实现中医的整体调节治疗。研究中药复方的配伍对推动中药现代化发展、新药开发以及临床应用有着重要意义。近年来,研究者们在传统的"七情和合"与"君臣佐使"的基础上,运用新技术和新方法对中药复方的成分、药效活性和药代动力学性质等进行了研究,从不同角度探讨了中药复方配伍的科学内涵。同时,多种数理方法和模型的建立、网络药理学和数据挖掘方法的发展与应用,也对中药复方配伍研究提供了很大帮助。研究方法的发展虽促进了中药复方配伍的科学研究,但还需进一步建立适合中药复方配伍复杂关系的研究方法,以阐明中药复方及其成分/组分配伍的内在规律,进而构建新的现代中药复方,这也是目前中药复方配伍研究的重点任务。     

Carboxylesterase catalyzed 18O-labeling of carboxylic acid and its potential application in LC-MS/MS based quantification of drug metabolites

LC-MS quantification of drug metabolites is sometimes impeded by the availability of internal standards that often requires customized synthesis and/or extensive purification. Although isotopically labeled internal standards are considered ideal for LC-MS/MS based quantification, de novo synthesis using costly isotope-enriched starting materials makes it impractical for early stage of drug discovery. Therefore, quick access to these isotope-enriched compounds without chemical derivatization and purification will greatly facilitate LC-MS/MS based quantification. Herein, we report a novel ¹⁸O-labeling technique using metabolizing enzyme carboxylesterase (CES) and its potential application in metabolites quantification study. Substrates of CES typically undergo a two-step oxygen exchange with H₂¹⁸O in the presence of the enzyme, generating singly- and doubly-¹⁸O-labeled carboxylic acids; however, unexpected hydrolytic behavior was observed for three of the test compounds – indomethacin, piperacillin and clopidogrel. These unusual observations led to the discovery of several novel hydrolytic mechanisms. Finally, when used as internal standard for LC-MS/MS based quantification, these in situ labeled compounds generated accurate quantitation comparable to the conventional standard curve method. The preliminary results suggest that this method has potential to eliminate laborious chemical synthesis of isotope-labeled internal standards for carboxylic acid-containing compounds, and can be developed to facilitate quantitative analysis in early-stage drug discovery.     

Study on therapeutic mechanism of Neiyifang in treating endometriosis

Objective: To observe the clinical effect of Neiyifang (NYF) in treating endometriosis and to explore its therapeutic mechanism through observing its influence on plasma β-endorphin (β-EP) in different menstrual stages and levels of prostaglandins (PGs) in menstruation.Methods:NYF was administered to 104 patients with endometriosis one dose daily with 3 successive menstrual cycles as one therapeutic course. Peripheral blood β-EP level in follicular, luteal and menstrual stages, as well as PGF_2α, PGE2, thromboxane B₂ and 6-keto-PGFl α levels in menstrual stage were detected by RIA, and controlled with those in 15 healthy persons.Results: (1) The total effective rate of NYF was 81.3% and it showed significant effect in improving patients’ clinical symptoms and physical signs; (2) In menstrual stage, the levels of β-EP, 6-keto-PGF_α/ TXB₂ were lower(P <0.05) and levels of PGF_2α, PGE₂, TXB₂ and 6-keto-PGF_1α were higher (P< 0. 05) in patients than those in control, and the higher the level of PGE₂, the severer the menalgia, (3) NYF could increase levels of β-EP, 6-keto-PGF_1α, and reduce levels of PGF_2α, PGE_2α in menstrual stage of patients (all P<0.05).Conclusion: (1) NYF has good clinical effect in treating endometriosis; (2) Patients’ symptom of menalgia is closely related with the excessive high levels of PGF_2α and PGE₂, PGI₂/TXA₂ ratio disturbance, and excessive low level of β-EP; (3) NYF could significantly decrease the PGE₂, PGF_1α levels, increase the 6-keto-PGF_1α/TXB₂ ratio and the level of β-EP, so as to alleviate the menalgia in patients with endometriosis. This item was supported by National Funds of Natural Sciences(No. 30070942)     

Clinical Application of Movement-needling Technique： Elbow and Wrist Sprains

Elbow Strain 1. Acupoints Primary acupoints: Quchi(LI 11), Zhouliao(LI 12), Shousanli(LI 10) and Ashi point.     

天冬胶作为血管栓塞剂毒性实验的初步报告

目的:从其毒性和相关特性方面研究天冬胶作为血管栓塞剂的可行性。方法:昆明小鼠腹腔注射天冬胶后观察外貌行为、食物消耗、体重情况。最后检测WBC、血小板、RBC和Hb浓度;测定血清ALT、肌酐和尿素氮浓度。病理检查心、肝、肾、脾、脑、腹膜、生精组织及腹壁肌肉。大腿肌肉注射天冬胶的小鼠1、3、7 d后各处死,取局部肌肉标本送病理检查。结果:1.仅实验组给药后第1天反应稍差及食量显著低于对照组(P<0.001)外,第2天起各组外貌行为无异常、食量无显著差异(均P>0.05)。2.各组小鼠的体重随时间而增加,除实验组2于实验1周后增长速度显著低于实验组1(P<0.02)和对照组(P<0.001)外,其他无显著差异。3.各组血WBC、血小板、RBC、Hb及血清ALT、肌酐和尿素氮浓度无显著差别。4.仅1个实验组小鼠肝脏内可见多灶性淋巴细胞和其他炎症细胞浸润区,其他组肝脏表现正常。实验组腹膜出现少许慢性炎症细胞的浸润和间皮细胞的增生。其他均无病理改变。大腿肌肉内仅见少许残留异物,无病理改变。结论:天冬胶使用安全、生物相容性较好,作为血管栓塞剂有较好的前景。     

CDP-c、硫酸镁联用对大鼠短暂脑缺血的神经保护作用

目的 研究胞二磷胆碱（CDP-c）、硫酸镁联用对大鼠试验性短暂局灶脑缺血的神经保护作用.方法 用大脑中动脉栓塞（MCAO）法制作短暂性（90min）局部脑缺血模型,观察CDP-c、硫酸镁单用及不同剂量联用7d后,Caspase-3阳性细胞数、神经功能缺损及脑梗死体积的变化.结果 和对照组相比,CDP-c、硫酸镁单用及两药联用组脑梗死体积较小,Caspase-3表达细胞数较少,并有统计学意义.两药联用组脑梗死体积均比单用组小,Caspase-3表达细胞数亦较两药单用组少（P＜0.05）.两药联用组相比各项指标均无显著意义（P＞0.05）.结论 CDP-c和硫酸镁单用对试验性短暂脑缺血模型可能具有神经保护作用.CDP-c与硫酸镁合用对短暂性试验性局灶脑缺血的神经保护可能有协同作用,并且可以减少各药的用量.     

高层次中医临床人才培养模式初探

根据本院名老中医工作室建立的战略思考、组织构架和运作方式及取得的初步成绩。探讨当今高层次中医临床人才的培养模式。     

慢性胃炎脾气虚证与脾胃湿热证的差异表达基因比较

目的：比较慢性胃炎脾气虚证与脾胃湿热证患者差异表达基因。方法:分别提取慢性胃炎脾气虚和脾胃湿热患者胃黏膜组织RNA各4例，逆转录荧光探针标记后杂交制作BiostarH-140 s基因芯片。采用荧光值ratio、生物信息学、t检验等方法分析结果，实时荧光定量PCR检测部分相关基因。结果:获得差异表达基因245条，主要为营养物质消化吸收运输、物质能量合成代谢、细胞周期增殖分化、免疫反应等相关基因；有显著意义的差异表达基因77条；实时定量PCR检测10条基因，6条与芯片结果一致。结论:慢性胃炎脾气虚和脾胃湿热2个证型基因表达存在明显差异，提示中医的临床辨证分型与基因差异表达有一定关系。